Quince Therapeutics

Quince Therapeutics

Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases.

HQ location
South San Francisco, United States
Launch date
Employees
Market cap
$49.5m
Enterprise value
$50m
Share price
$1.65 CRTX
Recent deals
Authorizing premium user...